Guangdong Hybribio Biotech Co (SZSE:300639) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Guangdong Hybribio Biotech Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.01.

Guangdong Hybribio Biotech Co's long-term debt to total assets ratio increased from Sep. 2023 (0.01) to Sep. 2024 (0.01). It may suggest that Guangdong Hybribio Biotech Co is progressively becoming more dependent on debt to grow their business.

Guangdong Hybribio Biotech Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co LT-Debt-to-Total-Asset Chart

Guangdong Hybribio Biotech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Guangdong Hybribio Biotech Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Guangdong Hybribio Biotech Co LT-Debt-to-Total-Asset Calculation

Guangdong Hybribio Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	45.671	/	5725.791
	=	0.01

Guangdong Hybribio Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	65.805	/	5093.63
	=	0.01

Guangdong Hybribio Biotech Co (SZSE:300639) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Guangdong Hybribio Biotech Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Guangdong Hybribio Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000

Website

http://www.hybribio.cn

Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Executives

Xie Long Xu	Directors, executives
Li Qing Hui	Executives
Wang Jian Yu	Directors, executives
Guan Zhi Sheng	Directors, executives
Qiu Mei Lan	Supervisors
Yuan Xian	Securities Affairs Representative
Tang You Gen	Independent director
Cai Dan Ping	Director
Chen Yi	Directors, executives
Xu Wan Jian	Supervisors
Huang Wei Xiong	Director
Guan Qiao Zhong	Directors, executives

Guangdong Hybribio Biotech Co Headlines

No Headlines